New Clinical Insights Into the Pathology of Amyloidosis

Slides:

Advertisements

Similar presentations

Eleventh International Symposium HEART FAILURE & Co. MORTE IMPROVVISA SUDDEN DEATH Reggia di Caserta, aprile 2011 Lamiloidosi: il danno cardiaco.

Advertisements

Case report no. 9. Recurrence of amyloid in a kidney allograft Eva Honsová Institute for Clinical and Experimental Medicine Prague, Czech Republic.

QUIZ OF THE WEEK By .. Shada AlGhamdi.

Amyloidosis Dr. Amitabha Basu.

Plasma cell disorders Dr. hassanali vahedian ardakani Medical oncologist hematologist 2013.

Pathologic Diagnosis in Amyloidosis

Biochemical and genetic evaluation in amyloidosis

Upfront Combination Therapy vs Step-Up Approach for PAH:

Significance of Fine Needle Aspiration Cytology and Vacuum-Assisted Core Needle Biopsy for Small Breast Lesions Satoko Nakano, Masahiko Otsuka, Akemi.

Diagnosis, Prognosis, and Management of aHUS

A Common Clinical Challenge: Neonatal Jaundice Is it Physiologic or Pathologic?

Making Decisions With Your Osteoarthritis Patients

Improving the Diagnosis and Treatment of Seizures in Long-term Care

Dry AMD and GA: The Present and Future

Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome

Merkel Cell Carcinoma: What Do Clinicians Need to Know?

Clues to a Diagnosis: A Focus on Light-Chain Amyloidosis

Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.

Seasonal Allergic Rhinitis

Amyloid Imaging for Alzheimer's Disease in Practice

Advances in Dry Eye.

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Updates in Neuronal Ceroid Lipofuscinosis

Checkpoint Inhibition

Globular amyloidosis Case 15.1 Chapter 15 1

Tuberous Sclerosis Complex Fundamental Concepts in Diagnosis and Management.

by Nelson Leung, Samih H. Nasr, and Sanjeev Sethi

Gene Therapy: Past, Present, and Future

Ask the Experts.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

When Is Biologic Therapy Appropriate for HS?

AG10-201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of AG10 versus Placebo in ATTR-CM Background Primary Endpoints Key Exclusion Criteria.

What Is Bipolar Disorder?

Managing Polycythemia Vera in the Community Setting

Program Overview. Major Depressive Disorder: The Challenging Patient and the Goal of Recovery.

Navigating Treatment Options in PAH

When Is Intrathecal Drug Delivery Appropriate?

Challenges in Severe Asthma

Understanding the Updated Guidelines for ALK Testing in NSCLC

Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.

The Amyloidoses Douglas A. Stahura 4/7/99.

Updates in Neuronal Ceroid Lipofuscinosis

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

AJKD Atlas of Renal Pathology: Hereditary and Other Non-AL Amyloidoses

Critical Decision Points in Insomnia

Incorporating Prostacyclins Into Practice

Challenges in LA SCCHN.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Naveen L. Pereira et al. JACC 2018;71:

Alect2 amyloidosis: primum non nocere (first, do no harm)

Clinical Challenges and Updates in Managing Seizure Clusters

When Is Intrathecal Drug Delivery Appropriate?

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

Volume 82, Issue 2, Pages (July 2012)

Incorporating New PAH Treatments Into Clinical Practice

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Binge Eating Disorder.

by Giovanni Palladini, and Giampaolo Merlini

Importance of Early Diagnosis and Management in SMA

Merging the Art and Science of Managing nOH in Clinical Practice

The Building Blocks of Homocystinuria and Homocysteinemia Management

Next-Generation Sequencing and ctDNA

Exploring the Use of Adeno-Associated Virus for Gene Therapy

Monoclonal Antibodies in Migraine Prevention: What the Primary Care Physician Needs to Know.

Ask the Psoriasis Expert

Working Together to Diagnose Idiopathic Pulmonary Fibrosis

Suggested algorithm for cardiac imaging diagnosis and stratification of cardiac amyloidosis. Suggested algorithm for cardiac imaging diagnosis and stratification.

Volume 5, Issue 5, Pages (May 1997)

Presentation transcript:

New Clinical Insights Into the Pathology of Amyloidosis

What is Amyloidosis?

Protein Structure A Brief Review

What Makes a Protein Amyloidogenic?

Amyloidoses Protein Folding Disorders

Amyloidoses Protein Folding Disorders

What Are Amyloidoses?

AL (Amyloid Light Chain)

External Signs of AL Amyloidosis

Hereditary Transthyretin Amyloidosis

Hereditary Transthyretin Amyloidosis

Wild-Type ATTR

AA Amyloidosis

ALECT2 Amyloidosis

Diagnosis of Amyloidosis

Diagnosis of Amyloidosis (cont)

Clinical Suspicion of Amyloidosis

Fine Needle Abdominal Fat Pad Biopsies

Sensitivity of Various Organ Biopsies in the Diagnosis of Amyloidosis

Diagnostic Algorithm for Systemic Amyloidoses

Key Points to Consider for Amyloid Protein Typing

Amyloid Protein Typing Challenges With Immunohistochemistry

Proteomic Analysis to Classify Amyloidoses

Genetic Testing

Determining an Appropriate Treatment Plan

Therapies in AL amyloidosis Targeting the Precursor Protein

Therapies in AA and ALECT2 Amyloidosis

Hereditary Transthyretin Amyloidosis Current Approaches

Concluding Remarks

Abbreviations